title: Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.
abstract: Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action. However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported. Prompt identification of the causal association and initiation of appropriate therapy should be instituted for this life threatening condition.
authors.affiliation: Section of Pulmonary and Critical Care Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USA.
authors.forename: Alehegn
authors.initials: A
authors.lastname: Gelaye
authors.affiliation: Department of Internal Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USA.
authors.forename: Abdallah
authors.initials: A
authors.lastname: Haidar
authors.affiliation: Department of Internal Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USA.
authors.forename: Christina
authors.initials: C
authors.lastname: Kassab
authors.affiliation: Section of Pulmonary and Critical Care Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USA.
authors.forename: Syed
authors.initials: S
authors.lastname: Kazmi
authors.affiliation: Section of Pulmonary and Critical Care Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USA.
authors.forename: Prabhat
authors.initials: P
authors.lastname: Sinha